SAN FRANCISCO, Jan 13 (Reuters) - AstraZeneca has agreed to buy Boston-based Modella AI, the companies said on Tuesday, as the drug industry increases its use of artificial intelligence to accelerate the discovery of new drugs.
The companies did not disclose financial terms. In a press release, Modella AI said its "foundation models" and AI agents would be integrated into oncology research and development to support clinical development and biomarker discovery.
"Oncology drug development is becoming more complex, more data-rich and more time-sensitive," said Gabi Raia, Modella AI's chief commercial officer, adding that joining AstraZeneca would allow it to deploy its tools in global trials and clinical settings.
AstraZeneca said that this was the first acquisition of an AI firm by a big pharmaceutical company.
In an interview at the JP Morgan Healthcare Conference, AstraZeneca Chief Financial Officer Aradhana Sarin said the acquisition would "supercharge" the company's quantitative pathology and biomarker discovery efforts by bringing more data and AI capabilities in-house.
The deal was one of a number of pacts between major drug firms and AI companies that were unveiled at the healthcare conference, including a $1 billion collaboration between Nvidia and Eli Lilly. They plan to build a new research lab using Nvidia's latest-generation AI chips.
Modella will accelerate AstraZeneca’s efforts to make pathology more quantitative - using computers to analyze biopsies for relevant proteins and correlate them with clinical data - so AstraZeneca can develop “highly targeted biomarkers and then highly targeted therapeutics,” Sarin said.
The deal is an expansion of a multi-year collaboration that the companies unveiled in July.
Sarin said that partnership served as a "test drive," adding that AstraZeneca ultimately wanted Modella's data, foundation models and AI talent in-house.
She said AI tools could be used to more rapidly select patients for drug trials, which could increase the odds of clinical success and cut related costs.
(Reporting by Maggie Fick; Editing by Thomas Derpinghaus)
LATEST POSTS
- 1
Astronomer captures 2 meteors slamming into the moon (video) - 2Russian authorities threaten WhatsApp with total ban
- 3In blow to Lula, Brazil Congress revives controversial environmental bill
- 4Yasser Abu Shabab's killing raises questions about Israel's militia strategy in Gaza
- 5Revealing the Incomparable Realms: An Excursion through Power and Inheritance
- Unfathomable and Entertaining Legal disputes That Surprise everyone
- AbbVie plans to build out its presence in obesity market
- Language Learning Stages: Which One Gets Your Vote?
- African nations push to recognize crimes of colonialism in Algeria
- The Best Business visionaries Under 30
- Accomplishing Balance between fun and serious activities: Procedures for a Better Life
- Hot Electric Vehicles for 2023
- Mali and Canadian miner Barrick agree to resolve tax dispute, ending 2-year standoff
- Washington state experiences historic flooding as Skagit River hits record high level. See flooding maps, highway closures and forecasts.
